

Supplementary Materials

Production of bioactive compounds from callus of *Pueraria thomsonii* Benth with promising cytotoxic and antibacterial activities



Fig. S1 Collection and callus induction of *P. thomsonii*, (S1a) Collected tender shoots of *P. thomsonii*. (S1b) Healthy and well grown callus of *P. thomsonii*




Fig. S2 Cytotoxic activity of A549, 4T1 and NC1-H1975; (S2a-c) calli extracts against A549, 4T1 and NC1-H1975; (S2d-f) standard drug doxorubicin against A549, 4T1 and NC1-H1975; (S2g-i) blank control without treatment of 4T1 and NC1-H1975, respectively




Fig. S3 Antibacterial activity of calli extracts of *P. thomsonii* using disc diffusion assay, (S3a) Plate showing antibacterial activity against *Staphylococcus aureus* (ATCC 43300, MRSA), (S3b) Methicillin resistant *Staphylococcus epidermidis* (ATCC 12228, MRSE), (S3c) *Klebsiella pneumoniae* (ATCC 13883)




Fig. S4 The HRESIMS spectrum of compound 1 (daidzin)




Fig. S5 The ^1H NMR spectrum of compound 1 (daidzin)




Fig. S6 The ^{13}C NMR spectrum of compound 1 (daidzin)




Fig. S7 The ^{13}C DEPT135 NMR spectrum of compound 1 (daidzin)




Fig. S8 The HRESIMS spectrum of compound 2 (puerarin)




Fig. S9 The ¹H NMR spectrum of compound 2 (puerarin)




Fig. S10 The ^{13}C NMR spectrum of compound 2 (puerarin)




Fig. S11 The ^{13}C DEPT135 NMR spectrum of compound 2 (puerarin)




Fig. S12 The HRESIMS spectrum of compound 3 (biochanin A)




Fig. S13. The ¹H NMR spectrum of compound 3 (biochanin A)




Fig. S14 The ¹³C NMR spectrum of compound 3 (biochanin A)




Fig. S15 The ¹³C DEPT135 NMR spectrum of compound 3 (biochanin A)




Fig. S16 The HRESIMS spectrum of compound 4 (daidzein)




Fig. S17 The ¹H NMR spectrum of compound 4 (daidzein)




Fig. S18 The ^{13}C NMR spectrum of compound 4 (daidzein)




Fig. S19 The ^{13}C DEPT135 NMR spectrum of compound 4 (daidzein)




Fig. S20 The HRESIMS spectrum of compound 5 (ethyl 3-(4-hydroxyphenyl)acrylate)




Fig. S21 The ¹H NMR spectrum of compound 5 (ethyl 3-(4-hydroxyphenyl)acrylate)




Fig. S22. The ¹³C NMR spectrum of compound 5 (ethyl 3-(4-hydroxyphenyl)acrylate)




Fig. S23 The ¹³C DEPT135 NMR spectrum of compound 5 (ethyl 3-(4-hydroxyphenyl)acrylate)




Fig. S24 The HRESIMS spectrum of compound 6 (liquiritigenin)




Fig. S25 The ¹H NMR spectrum of compound 6 (liquiritigenin)




Fig. S26 The ¹³C NMR spectrum of compound 6 (liquiritigenin)




Fig. S27 The ¹³C DEPT135 NMR spectrum of compound 6 (liquiritigenin)




Fig. S28 Cytotoxic activity of compounds **(1-6)** on 4T1: (S28a) daidzin, (S28b) puerarin, (S28c) biochanin A, (S28d) daidzein, (S28e) p-coumaric acid ethyl ester and (S28f) liquiritigenin




Fig. S29 Cytotoxic activity of compounds **(1-6)** on NC1-H1975: (S29a) daidzin, (S29b) puerarin, (S29c) biochanin A, (S29d) daidzein (S29e) p-coumaric acid ethyl ester and (S29f) liquiritigenin






Fig. S30 Cytotoxic activity of compounds **(1-6)** on A549: (S30a) biochanin A, (S30b) p-coumaric acid ethyl ester and (S30c) liquiritigenin






Fig. S31 Antibacterial activity of compounds **(1-6)** using disc diffusion assay (S31a). *K. pneumonia*, (S31b) MRSE and (S31c) MRSA